Understanding disease progression: The power of natural history studies

A natural history study is a preplanned observational study designed to track the course of a disease over time. Its purpose is to identify demographic, genetic, environmental, and clinical variables that correlate with disease development and outcomes. In rare and genetically defined conditions, where existing research is often limited and patient populations are small, these studies provide the foundational data that informs treatment development, endpoint selection, and trial design.

Key Takeaways

• Natural history studies track disease progression in untreated forms to provide essential baseline data.
• These studies are critical for rare diseases where existing research and clinical data are limited.
• Insights help researchers identify disease variability and specific patient subtypes.
• Data from natural history studies is used to optimize clinical trial design and accelerate drug development.

Why natural history studies matter in precision medicine

Natural history studies serve several distinct functions that are critical to precision medicine programs, particularly in rare disease. 

Characterizing disease progression

NHS track how a condition evolves across patients over time, capturing the range of clinical presentations, the rate of progression, and the variability between subgroups. This data describes the features and evolution of a disease, both retrospectively and prospectively.

Informing drug development

By establishing what happens in the absence of intervention, NHS provide the baseline against which therapeutic effects are measured. This is particularly important in rare diseases, where randomized placebo-controlled trials may not be feasible or ethical.

Defining endpoints and eligibility criteria

NHS data reveals which clinical markers change meaningfully over time and which patient subgroups are most likely to benefit from intervention. This directly shapes protocol design, from inclusion and exclusion criteria to primary and secondary endpoints.

Supporting regulatory strategy

The FDA recognizes natural history studies as a key input for rare disease drug development. NHS data can be used to establish external control arms, justify single-arm trial designs, and contextualize treatment effects for regulatory review.

Identifying and connecting with patients 

NHS create a mechanism for building recontactable patient populations. Participants who enroll in an NHS can be engaged for future research, reducing the time and cost of recruitment for subsequent interventional studies.

Our report explores these themes in greater detail, including real-world examples such as the Duchenne Natural History Study that demonstrate how NHS have shaped the trajectory of treatment development. 

Why natural history studies require coordinated infrastructure

Running a natural history study in a rare or genetically defined disease is not simply a matter of observation. It requires identifying patients who may be geographically dispersed and diagnostically underserved, engaging them over extended time periods, and collecting consistent, high-quality data across clinical, genetic, and environmental variables.

These requirements create specific operational challenges:

• Patient identification: In rare diseases, eligible participants are difficult to find through traditional site-based methods. Omni-channel recruitment, genetic database screening, and advocacy partnerships are often necessary to reach the right populations.
• Genetic characterization: Many NHS in precision medicine require genetic testing to define or stratify the study population. This introduces logistical and consent-related complexity, particularly when testing is conducted remotely.
• Longitudinal engagement: NHS collect data over months or years. Maintaining participant trust and engagement throughout that period requires ongoing communication, return-of-results pathways, and responsive support workflows.
• Recontact for future research: One of the most valuable outcomes of an NHS is the ability to reconnect with characterized patients for subsequent interventional studies. This requires compliant, consent-aware recontact infrastructure from the outset.

When these elements are managed through disconnected vendors and manual processes, data quality degrades and participant attrition increases. A unified approach — one that connects patient finding, genetic testing, engagement, and recontact within a single compliant system — reduces these risks and preserves the long-term value of the study.

The full report is available for download below.

To learn how Sano supports natural history study design and execution across the participant lifecycle, get in touch.